Halozyme Therapeutics, Inc. · NASDAQ:HALO

Halozyme Therapeutics — Investor Presentation (February 2007)

29 slides from Halozyme Therapeutics's investor presentation, Feb 22, 2007

  1. Slide 1: Company Overview February 2007

    Company Overview February 2007

  2. Slide 2: Safe Harbor

    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. All statements made in this presentation that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements could be affe

  3. Slide 3: Investment Highlights

    HTI develops and commercializes biotechnology products based on versatile family of hyaluronidase enzymes Unique portfolio of assets with best-in-class partners and near-term catalysts Enhanze Technology: Novel drug delivery platform that can lead to value-creating partnerships; e.g., $612M partners

  4. Slide 4: Halozyme Therapeutics, Inc.

    San Diego-based biopharmaceutical company, incorporated in 1998 Listed on American Stock Exchange (ticker: HTI) Cash position at end of Q3 2006 - $16.1 million Additional $31 million received from Roche in December 2006 and $31 million from Baxter in February 2007 Market capitalization - $600 millio

  5. Slide 5: Halozyme's Core Competence

    Development and commercialization of biotechnology products with rapid time to market Initial molecular biology activities ? NDA submission in 21 mos. NDA submission ? FDA approval in 8 1/2 months High productivity with effective resource allocation and capital efficiency 2 U.S. FDA approvals achiev

  6. Slide 6: Product Pipeline

    Product Target/ indication(s) HYLENEX* Drug & fluid infusion Chemophase(tm) Bladder cancer Enhanze(tm) Technology Large molecule therapeutics (e.g., MoAb's) rHuPH20 IV Oncology, neurology, cardiology HTI-101 Oncology Research Pre- clinical Phase 1 & 2 Phase 3 In registr- ation Marketed product Devel

  7. Slide 7: What Are Enhanze Technology and HYLENEX?

    Different formulations of recombinant human hyaluronidase (rHuPH20) rHuPH20 is a 61kD naturally- occurring human enzyme that temporarily breaks down hyaluronic acid (HA) Hyaluronidases have been safely used clinically for more than 60 years to enhance the dispersion of co-injected drugs 3-D model of

  8. Slide 8: rHuPH20 Hyaluronidase: Mechanism of Action

    rHuPH20 Hyaluronidase: Mechanism of Action

  9. Slide 9: Enhanze Technology vs. HYLENEX

    Enhanze Technology High unit dose of rHuPH20 for use with large molecule therapeutics (e.g. monoclonal antibodies) and proprietary small molecules Key partnership with Roche (market leader in biologics) Scaleable business development model and partnership opportunities HYLENEX Low unit dose of rHuPH

  10. Slide 10: Enhanze Technology: For Partners with Injectable Drugs

    Decrease pain and tissue distortion upon injection Reduce adverse injection site reactions Change route of administration (e.g., IV to SC) Potentially increase dosing interval Convenience & compliance Extend product lifecycle of drugs coming off patent Provide differentiation for multi-sourced drugs

  11. Slide 11: Enhanzed Commercial Anti-Rheumatic Monoclonal Antibody bioavailability

    0.0E+00 2.0E+05 4.0E+05 6.0E+05 8.0E+05 1.0E+06 1.2E+06 1.4E+06 1.6E+06 1.8E+06 2.0E+06 0 10 20 30 40 50 60 70 80 90 100 110 120 130 Time (Hours) Serum Antibody Levels (I-125Counts/ml) in rats IgG 10mg/kg local Bioavailability =59 +/- 7% Enhanzed(tm) Commercial Anti- Rheumatic Monoclonal Antibody Ig

  12. Slide 12: Enhanzed Commercial Interferon bioavailability

    0.0E+00 5.0E+04 1.0E+05 1.5E+05 2.0E+05 2.5E+05 3.0E+05 3.5E+05 4.0E+05 0 10 20 30 40 50 Time (Hours) Local Serum Interferon Levels (I-125 Counts/ml) in rats Bioavailability =61% Local +rHuPH20 Intravenous Local Local +rHuPH20 Enhanzed(tm) Commercial Interferon

  13. Slide 13: Enhanze Technology Deal with Roche Worth up to $612M

    Enhanze Technology Deal with Roche Worth up to $612M Pre-clinical at Roche's request API manufacturing Regulatory support for rHuPH20 part of filing(s) $20M up-front and up to $111M in milestones for first 3 targets $11M equity purchase (25% premium) Up to $47M per target in up-front and milestones

  14. Slide 14: Key Takeaways from Roche Deal

    Source: Business Insights (Future of Monoclonal Antibodies, 2006); HTI analysis Key Takeaways from Roche Deal Roche deal validates HTI's Enhanze Technology and business model Roche is one of the global leaders in development and commercialization of biologics Some of their leading products include M

  15. Slide 15: HYLENEX: A Breakthrough Innovation

    HYLENEX: A Breakthrough Innovation

  16. Slide 16: HYLENEX: For Drug and Fluid Infusion

    Labeled indications "For use as an adjunct to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; as an adjunct in subcutaneous urography for improving the resorption of radiopaque agents." Product Highlights Approved by FDA in December 2005 HYLENEX sales and marketi

  17. Slide 17: Intravenous Access: When Things Go Right...

    "It's tough to deal with kids and their parents if you have to stick them several times to start the IV..." "After we have tried and failed, we give up and call an outside specialized company... that's about half the time and it adds significant cost" Intravenous Access: When Things Go Right...

  18. Slide 18: Intravenous Access: When Things Go Wrong...

    Bruising Infiltration Infection Phlebitis Extravasation Extravasation + 10 days Intravenous Access: When Things Go Wrong...

  19. Slide 19: HYLENEX for EASi: Enzymatically Augmented SC Infusion

    Starting a subcutaneous infusion site is easy for the caregiver . . . .. . . and convenient for the patient, even at home Can use butterfly needle Can insert SC anywhere in the body (no misses) Especially useful for: Patient with poor venous access Agitated patients who repeatedly remove their IV li

  20. Slide 20: INFUSE-LR Study

    Baseline Baseline Mid-Infusion (200 cc) Mid-Infusion (200 cc) INFUSE-LR Study End-Infusion (400 mL) End-Infusion (400 mL) Side-by-Side Simultaneous Sub-Q Infusions Randomized controlled Phase IIIB study of subcutaneous hydration of lactated Ringer's (LR) +/- HYLENEX in 54 volunteer subjects HYLENEX

  21. Slide 21: HYLENEX: Sales & Marketing Strategy with Baxter

    Build a strong clinical foundation with post-marketing trials to drive adoption in multiple settings of care (e.g., INFUSE-LR) Educate clinicians about benefits of Hylenex by engaging key opinion leaders and enrolling clinical Centers of Excellence Make Hylenex commercially available for drug and fl

  22. Slide 22: Hylenex Deal with Baxter Worth up to $65M

    Hylenex Deal with Baxter Worth up to $65M Development help at Baxter's request API manufacturing HTI owns all regulatory files $10M up-front and up to $25M in milestones $10M in prepaid royalties through 2009 $20M equity purchase (25% premium) Baxter covers all development, clinical, regulatory, and

  23. Slide 23: Key Takeaways from Baxter Deal

    Key Takeaways from Baxter Deal Baxter deal validates Hylenex and product potential Baxter is one of the global leaders in IV fluids and medication delivery and has strong clinicians relationships and channel strength Expanded rights now include global rights, as well as kits and co- formulations wit

  24. Slide 24: Chemophase: For Superficial Bladder Cancer

    Chemophase: For Superficial Bladder Cancer

  25. Slide 25: Chemophase: For Superficial Bladder Cancer

    Chemophase: For Superficial Bladder Cancer

  26. Slide 26: Randomized Clinical Trial of Bovine PH20 in Bladder Cancer

    Mitomycin Mitomycin + Bovine PH20 Mean age (range) 62.8 (44-80) 67.3 (49-84) Men/Women 17/11 18/10 Primary tumors 15 16 Recurrent tumors 13 12 Mean Follow Up (range) 21.1 (6-32) 20.2 (6-32) Tumor Recurrence (%) 9/28 (32.1%) 2/28 (7.1%) P<0.05 P<0.05 Source: Maier and Baumgartner, 1989 Randomized Cli

  27. Slide 27: Penetration of Chemotherapy with Chemophase in Bladder Cancer

    Penetration of Chemotherapy with Chemophase in Bladder Cancer Chemotherapy alone Chemotherapy with Chemophase

  28. Slide 28: Chemophase Market Opportunity in Superficial Bladder Cancer

    63,210 new cases of urinary bladder cancer in the US1,2 499,199 prevalent cases of urinary bladder cancer3,4 At least 6 treatment cycles of mitomycin and Chemophase Source: 1 American Cancer Society, 2005; 2 ~70% of new cases are "superficial" disease (AUA Bladder Cancer Guidelines Panel, 1999); 3 N

  29. Slide 29: 2007 Milestones

    Milestones Announce results of ENHANZE(tm) clinical trial, 1Q07 INFUSE-Morphine trial for HYLENEX, 1Q07 HYLENEX commercial launch, 2Q07 Complete Enrollment of Chemophase Phase I/IIa clinical trial, 3Q07 Ongoing Activities Initiate more ENHANZE clinical studies for Enhanze(tm) Technology Baxter to in

Halozyme Therapeutics — Investor Presentation (February 2007) on 6ix